Cell toxicity and conformational disease

Robin W Carrell1

  • 1Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK CB2 2XY. rwc1000@cam.ac.uk

Trends in Cell Biology
|October 6, 2005
PubMed

Insights

Protein misfolding causes neurodegenerative diseases like Alzheimer's. Cytotoxicity arises from early aggregation stages, not just amyloid, highlighting intracellular processes and the need to study these mechanisms.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Late-onset neurodegenerative diseases stem from protein misfolding and aggregation.
  • Research has overemphasized extracellular amyloid deposits, neglecting intracellular disease mechanisms.

Purpose of the Study:

  • To shift focus to intracellular protein aggregation as a primary driver of neurodegeneration.
  • To investigate the cytotoxic mechanisms preceding amyloid formation.

Main Methods:

  • Analysis of structural findings in proteinopathies.
  • Review of studies on Alzheimer's disease and other dementias.
  • Examination of intracellular accumulation of misfolded proteins (e.g., alpha-1-antitrypsin, neuroserpin).

Main Results:

  • Cytotoxicity can occur from minor protein conformational changes without amyloid formation.
  • Intracellular accumulation of misfolded proteins in organelles like the endoplasmic reticulum is cytotoxic.
  • Damage in diseases like Alzheimer's initiates at early intermolecular linkage stages before amyloid.

Conclusions:

  • Intracellular protein aggregation, not solely amyloid, is key to neurodegenerative disease pathogenesis.
  • Understanding early aggregation events is crucial for elucidating disease mechanisms.
  • Further research is needed to detail the mechanisms of intracellular cytotoxicity in proteinopathies.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutations01:39

Mutations

Overview